Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2018

治療歴のある中等度または重症RAにおけるバリシチニブ: NICE Single Technology Appraisal における Evidence Review Groupの展望A

Pharmacoeconomics 2018 Jul; 36(7):769–78

Ren S,

Wong R,

Young A,

In this National Institute for Health and Care (NICE) single technology appraisal of baricitinib (BARI) monotherapy and combination therapy with methotrexate (MTX), BARI efficacy was considered comparable to bDMARDs and a cost-effective use of National Health Service (NHS) resources.NICE is an independent organisation responsible for providing national guidance on health technologies in England. To be recommended by NICE, the company must provide evidence to prove BARI’s effectiveness, both clin...

Keywords:

関節リウマチにおける抗リウマチ薬後のトファシチニブ: NICE Single Technology Appraisal における Evidence Review Groupの展望

Pharmacoeconomics 2018 Sep; 36(9): 1063–72

Wong R,

Young A,

In this National Institute for Health and Care (NICE) single technology appraisal of tofacitinib (TOF) plus methotrexate (MTX), TOF had similar efficacy and comparable costs to recommended bDMARDs plus MTX in patients with RA. NICE is an independent organisation responsible for providing national guidance on health technologies in England. To be recommended by NICE, the company must provide evidence to prove TOF’s effectiveness, both clinically and costly. This evidence based review, reports the...